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Patients suffering from end-stage heart failure refractory to optimal medical treatment may 
require a durable left ventricular assist device (LVAD) as a bridge to transplant or as destination 
therapy.  Unfortunately, as many as 40% of LVAD recipients experience right ventricular failure 
(RVF) post-implant. RVF post- implant results in a decrease in survival to transplant or continued 
support, and an increase in hospital stay. In the most severe RVF cases, mechanical circulatory 
support (MCS) for the right ventricle (RV) is needed.  Short-term RV MCS is available; however, 
no durable RVAD currently exists.  To date, research has focused mainly on predicting cases of 
RVF which occur immediately following LVAD implant or within the first 30 post-operative days.  
However, chronic RVF may also occur in subjects beyond one month. 
In the clinical setting, echocardiography (echo) and right heart catheterization (RHC) are 
standard methods used to provide imaging and hemodynamic data for physicians.  RHC reports 
resistance faced by the RV using only mean pressure and mean flow.  However, it does not account 
for the oscillatory component of pulsatile blood flow generated during the cardiac cycle. 
Pulmonary vascular impedance (PVZ) completely characterizes the RV afterload by measuring 
both steady and oscillatory components in the frequency domain. Unfortunately, PVZ has not been 
used in the clinical setting due to technical limitations and cost-prohibitive equipment.  
In this study, we attempted to calculate PVZ using signals obtained via standard of care 
echo and RHC, available before and during LVAD implantation. PVZ spectra were then used to 
 v 
determine if there is a difference in RV afterload based on RVF outcome within one year of 
implant. Results ultimately showed that there was no difference in afterload between groups.  
Though no difference in PVZ was found, the study showed that PVZ calculation is possible 
and may be of benefit to other patients. Following completion of the initial study, a graphically 
driven,  software-based system was developed to calculate PVZ using only standard of care data 
from electronic health records. The software facilitates rapid assessment of PVZ in a manner that 
is intuitive to those who work in the clinical setting. 
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The purpose of this work is to describe the pulsatile load encountered by the right ventricles 
of patients receiving left ventricular assist devices to determine if there is a difference between 
those who suffer from right ventricular failure post implant, versus those who do not.  In addition, 
this work attempts to create a solution to the hurdles that have previously limited the use of 
pulmonary vascular impedance in the clinical setting.  
This will require a basic understanding of ventricular function, ventricular failure, 
ventricular assist devices, and the methods used to assess the hemodynamics experienced during 
implantation. This chapter will briefly cover these topics.  
1.1 Normal Cardiac Function 
1.1.1 Cardiac Anatomy and the Cardiac Cycle 
The heart is a four-chambered muscular organ responsible for pumping blood to the organs 
throughout the body. The blood delivers oxygen and nutrients to organs in the body while also 
removing waste and carbon dioxide generated by cells. The heart can be thought of as two pumps 
in one (left and right), separated by a septal wall, connected in series in a closed loop. As shown 
in Figure 1, the left side of the heart is responsible for receiving oxygenated blood from the lungs 
and pumping it to organs such as the brain and kidneys (the systemic circuit), while the right side 
is responsible receiving de-oxygenated blood returning from end organs, and then pumping it to 
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the lungs (pulmonary circuit). Each side has two chambers: the atrium and ventricle.  The atria 
assist with filling of the ventricles which are the main pumping chambers of the heart.  The right 
ventricle (RV) and left ventricle (LV) pump blood through the pulmonary and systemic circuits, 
respectively.  
The atria and ventricles are separated by valves that ensure unidirectional flow. Between 
the left atrium (LA) and LV is the mitral valve, and between the right atrium (RA) and RV is the 
tricuspid valve.   These valves open when the ventricles relax during filling, or diastole, and close 
when the ventricles contract during ejection, or systole. The valves between the LV and Aorta 
(AO) and between the RV and Pulmonary artery (PA) are the aortic valve and pulmonic valve, 
respectfully. These valves are closed during diastole, and open during systole.  In between systole 
and diastole, there exists two phases where all valves are closed. They are referred to as 
isovolumetric contraction and isovolumetric relaxation. The entire process of filling and ejecting 
is called the cardiac cycle.  The frequency of the cardiac cycle is the heart rate (HR). The volume 
of blood that is ejected per beat is referred to as the stroke volume (SV). The periodic ejection of 
blood by the ventricles into the PA and AO generates pulsatile blood flow.  
Although both ventricles eject blood from the heart, they are very different in shape and 
wall thickness. The LV is an ellipsoidal shaped muscular chamber. This is due to high vascular 
resistance generated by the systemic circuit, which the ventricle must overcome to pump blood 
throughout the body.  Typically, the septum is treated as part of the LV, however, it still contributes 
to RV contraction. The RV is a thin-walled complex crescent shape that attaches to and wraps 
around the right side of the LV. The RV free wall is less muscular and requires less force to eject 
blood because it pumps into a low resistance, high compliance pulmonary circuit.  This will be 





Figure 1- Diagram of blood flow, basic cardiac anatomy, and major vessels. Solid blue indicates de-
oxygenated blood; solid red indicates oxygenated blood; dark maroon indicates myocardium and valves.  
(Left) Long axis view of heart with arrows indicating normal direction of blood flow in heart and great 
vessels. (Right) Short axis view of ventricles illustrationg thin-welled crescent shape of right ventricle, 
attached to circular left ventricle plus septum with thick walls 
1.1.2 Preload, Afterload, and stroke volume 
The total amount of blood that is ejected per unit time (typically in liters per minute for 
humans) is referred to as the cardiac output (CO) and is the product of SV x HR. This means that 
the CO ultimately increases or decreases with changes in heart rate or with stroke volume to meet 
the body’s demands. For instance, CO increases during exercise, and decreases at rest. The normal 
ventricle typically ejects between 50-70% of the end diastolic volume.  This percentage is referred 
to as the ejection fraction (EF).  The SV is determined by the end-diastolic volume (EDV) and 
resulting end-diastolic pressure (EDP), also known as pre-load. The more the ventricle fills, the 
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greater the pre-load. Preload affects wall stress  (σ) of either ventricle.  When assumed to be a 
sphere, σ is a product of the pressure (P) and ratio or the radius r divided by twice the wall thickness 
(h),  as per the Law of Laplace.  The greater the preload, the greater the wall stress, and the harder 
the ventricle contracts, which is the basis of the Frank-Starling Law of the Heart. The force 
generated by the ventricle at a given pre-load is referred to as the contractility. Contractility is 
controlled by the autonomic nervous system, it can also be increased or decreased by certain 
medications referred to as positive and negative inotropes, respectively. [1]  
The afterload is ultimately what the ventricle is pumping against. It is the source of wall 
stress during cardiac contraction and influences stroke volume opposite that of pre-load. With an 
increase in afterload comes a decrease in stroke volume. Afterload is composed mainly of steady 
resistance, which is the mean pressure divided by mean flow.  However, due to the pulsatile flow 
generated by the heart, there are additional oscillatory components of afterload that the heart 
encounters, which include inertance of blood, wave reflection and vascular compliance.   
Both ventricles encounter afterloads composed of resistance, compliance, inertance, and 
wave reflection.  However, the degree to which RV and LV afterload is influenced by each 
afterload component differs due to location of the main sources of compliance and wave reflection 




1.2 Heart Failure 
Heart failure (HF) is the inability to supply adequate blood flow to meet the body’s 
metabolic demand. Heart failure with reduced ejection fraction (HFrEF) comprises approximately 
49% of HF cases, while heart failure with preserved ejection fraction (HFpEF) comprises 
approximately 51% of HF cases.[4] As of 2017 the death rate (age adjusted) with any mention of 
heart failure was 89.7 per 100,000 in the United States, with a total of 80,480 deaths (36,824 males 
and 43,656 females). The one-year case fatality rate for HF is 29.7%. The economic impact is 
significant as well. In 2012, the cost of heart failure was 30.7 billion dollars, and is expected to 
double by 2030. [5]. (Since HFpEF patients are typically not candidates for MCS, focus will be 
placed on patients with HFrEF in this document). 
The severity of HF is classified by New York Heart Association Functional Class I-IV, 
with class IV being the most severe.[4] In the early stages of heart failure medical therapy may 
provide adequate support for patients.  However, as dilation continues and EF decreases (Figure 
2) wall stress increases as previously described by the Law of Laplace.  The myocardial thickness 
may increase to initially compensate for dilation. Unfortunately, such remodeling will only help 
for a short time due to increased energy requirements in an already failing ventricle, resulting in 
further decline. If a patient’s HF remains refractory to optimal medical treatment, heart 
transplantation may need to be considered.  Although heart transplantation remains the gold 
standard for treating end stage heart failure, donor hearts are in limited supply; additionally, some 




Figure 2- Dilation of the ventricles during ventricular failure.  (Left) Long axis and short axis diagram of a 
normal heart.  (Right) Long axis and short axis diagrams of dilation cause by left ventricular failure and 
reducedd cardiac output. Thickness of white arrows indicate proportinal differences in flow. 
1.3 Standard of Care Hemodynamic Assessment 
To study how a patient’s heart is performing, a mix of imaging and hemodynamic studies 
must be obtained.  Two of the most common means of assessing cardiac function include 
echocardiography (echo) and right heart catheterization (RHC). There are additional procedures, 
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such as CT Scans, MRI, and nuclear studies that may be ordered by physicians, however this work 
will focus echo and RHC. [4] 
1.3.1 Echocardiography and Pulsed-wave Doppler Velocity 
Echocardiography involves the use of high-frequency ultrasound waves to study the 
anatomy and function of the heart.  The soundwaves are emitted by a probe that is placed on a 
patient’s chest (transthoracic echo, or TTE), or down a patient’s esophagus and into the stomach 
(transesophageal echo, or TEE). [7, 8] The soundwaves that are emitted reflect aback to the probe 
at a shifted frequency. In 2D Echo, an image of the heart is formed by the difference in the two 
frequencies and shows wall and valve motion.   
During the same procedure, an additional signal is acquired called pulsed wave doppler 
velocity.  Like 2D images, a sound wave is emitted by the same probe.  The frequency of the 
soundwaves either increase if blood flow is moving towards the probe or decrease if they are 
moving away due to the Doppler Effect.  The resulting signal difference produces a spectrogram 
as shown in Figure 3 .  Because the frequency emitted and received is known along with the speed 
of sound in blood, the velocity of blood flow at a selected location can be measured by tracing the 
maximal frequency of the spectrogram. If the diameter of the vessel where the signal is measured 
is known (in this case the PA) the velocity can be multiplied by the cross sectional area (¼ the 
diameter squared) to calculate instantaneous flow (Q(t)). 
Advantages  of echocardiography include that it is noninvasive, relatively inexpensive, and 
therefore widely available. Limitations include conditions which may impair image acquisition, 
such as obesity and lung disease. Additionally, image quality is dependent upon the sonographer. 
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Figure 3- Pulsed-wave Doppler velocity of pulmonary artery.  The two-dimensional image sector at the top of 
the image shows the location where the pulsed-wave doppler velocity is being measured. The periodic signal is 
the doppler signal converted to velocity. The electrocardiogram of the heart is superimposed at the bottom of 
the image. 
1.3.2 Right Heart Catheterization 
Right heart catheterization is the most direct method by which pressure and output in the 
heart can be measured.  It is an invasive procedure that requires the insertion of a fluid-filled tube 
(catheter) into the jugular vein (or alternatively into the femoral vein via the groin), and then 
introducing it into the heart via the RA. It is then advanced across the tricuspid valve into the RV, 
and proceeds through the RV outflow tract (RVOT) into the pulmonary arteries.  Instantaneous 
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pressure waveforms are recorded throughout the procedure via a pressure transducer at the other 
end of the lumen.  The catheter is advanced into the smaller branches of pulmonary arteries until 
a balloon at the tip is inflated.  The balloon occludes the vessel and thereby allows measurement 
of the back pressure, referred to as the pulmonary capillary wedge pressure (PCWP), which 
estimates the pressure in the LA and at end-diastole in the LV.  The catheter, its path, and the 
waveforms measured in each chamber or vessel are shown in Figure 4. [9] 
The fluid-filled Swann-Ganz catheter does have limitations. Its signal is susceptible to 
motion artifacts, sometimes referred to as “catheter whip”. Air bubbles in the lumen or transducer 
may dampen the signal. Also, the physical properties of the lumen may either amplify or dampen 
certain aspects of a pressure signal due to the catheter’s frequency response.   
Advances in technology have addressed the shortcomings of fluid filled catheters.  High-
fidelity micromanometer wires which have a solid-state pressure sensor at the distal end have a 
higher signal-to-noise ratio than a fluid-filled catheter; these micromanometers are frequently used 




Figure 4- (Top) Swann-Ganz catheter with balloon tip inflated. (Left) Diagram of path taken by Swann-Ganz 
catheter (green) when introduced via jugular vein, through the superior vena cava, into the right atrium (RA), 
then right ventricle (RV), and eventually into the pulmonary artery (PA). When advanced into smaller vessels 
followed by inflation of the balloon tip, the back pressure from the left atrium, referred to as the pulmonary 
capillary wedge pressure (PCWP) can be measured. (Right) Pressure waveforms obtained during right heart 
catheterization in each reagion as the catheter proceeds forward in the same direction as blood flow. 
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1.4 Pulmonary Vascular Impedance 
The most comprehensive means by which the RV afterload can be assessed is via 
pulmonary vascular impedance (PVZ). PVZ was introduced by Milnor et al in the 1960’s [10, 11]. 
It describes both the steady and pulsatile resistance experienced by the RV during ejection. PVZ 
is not a single value; instead, it must be plotted as a function of values in the frequency domain 
(z).  To calculate PVZ(z), pressure and flow waveforms must be obtained in the time domain.  The 
waveforms are then decomposed via Fast Fourier Transform (FFT) into wavelets at each harmonic. 
Impedance modulus PVZ(z) is calculated as the ratio of pressure to flow in the frequency domain. 
The zeroth harmonic (z=0, or Z0) is equivalent to mean resistance, or total pulmonary resistance 
(TPR). The first harmonic (Z1), also referred to as the fundamental frequency, is the inverse of 
heart rate, and each subsequent harmonic is a multiple of the fundamental frequency (e.g. if HR is 
60 bpm, then z1 is 1 Hz, and z2 is 2 Hz, and so on). (See Figure 5). 
In addition to Z0, the first and second harmonic contain a large amount of power and 
represent the total stiffness (or the inverse of compliance) of the pulmonary vasculature and are 
influenced by wave reflection. The higher harmonics (Z2 through Z10) represent impedance of the 
proximal vessels without wave reflection.  The mean value of PVZ at higher harmonics is called 




Figure 5- Visual depiction of calculating pulmonary vascular impedance (PVZ) and the resulting spectrum.  
(Top left) Pulmonary arterial pressure and pulmonary arterial flow are recorded in the time domain. (Bottom 
left) Waveforms are decomposed into wavelets and described in the frequency domain via Fast Fourier 
Trasnform (FFT) staring at the fundamental frequency z(1), (first harmonic, which is inverse of heart rate) 
and subseqent multiples of the first harmonic. (Top right) PVZ is calculated as the ratio of flow tow to pressure 
in the frequency domain. (Bottom right) Results of the modulous of PVZ are displayed visually as a 2D plot of 
PVZ(z) vs z.   
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1.5 Left Ventricular Assist Devices 
Left ventricular assist devices (LVADs) are a form of mechanical circulatory support 
(MCS) that are implanted in a patient suffering from end-stage left ventricular failure. There are 
multiple forms of mechanical circulatory support devices that are now available to assist LV 
outside of the operating room, all of which are responsible for unloading the LV and providing 
adequate perfusion to the systemic circuit.  These include temporary devices such as catheter-
based intra-aortic balloon pumps (IABPs) and micro-axial pumps, extracorporeal membrane 
oxygenation (ECMO), and temporary paracorporeal devices.  Such temporary devices can only be 
used for days to weeks before they must be removed, and severely limit a patient’s ability to 
ambulate. There are also long-term left ventricular assist devices that are implanted in patients’ 
chests and provide support for months to years.  These “durable” LVADs are the focus of this 
study and may be referred to as either “LVADs” or “durable LVADs” interchangeably for the 
remainder of this document.    
As shown in Figure 6, an LVAD is connected at the apex of the LV via inflow cannula and 
the outflow graft is anastomosed to the ascending aorta. The device is powered and controlled by 
a single transcutaneous driveline that exits the patient’s skin at the abdomen and connects to a 
controller and power source.  
 The Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS), 
which is a registry containing data from 58 sites in the United States that implant FDA approved 
mechanical MCS devices, reports that from June 2006- December 2018, there have been 24,354 
LVADs implanted (this excludes investigational devices). [12] 
 14 
 
Figure 6- Image reconstructions from CT scans of patients with left ventricular assist devices (LVADs) 
connected to apex of left ventricle and ascending aorta. (Left) First generation HeartMate XVE pulsatile 
LVAD, which contained a large pusher plate and valves to ensure unidirectional flow. (Right) Second 
generation HeartMate II, a valveless continuous flow LVAD which required a much smaller surgical pocket 
for implantation and could be used on smaller patients.  Adapted from reference number [13].  
1.5.1 Current Designs 
First-generation LVAD designs attempted to mimic the pulsatile nature of the native 
ventricle.  Unfortunately, they were too big for all but the largest of patients. Those who did receive 
an LVAD had to remain connected to large drive systems, had limited mobility, and were required 
to remain in- or close to the hospital. Originally these devices were only used on patients as a 
bridge to transplantation. However, it was shown that the same devices could be used even longer 
periods of time when a transplant was not an option.[14] Still, when an LVAD was originally 
shown to provide better survival than optimal medical therapy, much improvement was needed in 
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both areas.  LVADs at the time were still too large for many and were susceptible to mechanical 
failure and thrombus formation. 
Continuous flow ventricular assist devices, often referred to as 2nd and 3rd generation 
VADs, have replaced the original, larger, pulsatile VADs. The change in design paradigm has 
significantly decreased the size of VADs, making them available for more patients. For continuous 
flow VADs, blood is driven by a single moving part, the impellor, which is held in place by a 
mechanical bearing in the case of 2nd generation devices, or in the case of 3rd generation devices, 
by a hydrodynamic thrust bearing or full magnetic levitation. The single moving part increases the 
longevity of the device, and decreases the likelihood of adverse events such as stroke or mechanical 
failure. [15] The three main devices implanted at UPMC Presbyterian Hospital during this work 
were the HeartMate II LVAD (Abbott), HeartWare HVAD (Medtronic), and The HeartMate 3 
LVAD (Abbott), which are shown in Figure 7. 
The HeartMate II is an axial flow device, where the blood flows along the long axis of the 
pump.  A mechanical bearing holds the impellor in place. The HeartWare and HeartMate 3 devices 
are centrifugal devices, where the impellor drives blood out at a 90-degree angle from which it 
enters the device, allowing for a lower profile against the heart when implanted.  The impellors for 
both devices have no mechanical bearing, increasing durability.  [16, 17]   One drawback of these 
devices is the non-physiologic flows generated by the impellors. Areas of flow stasis and 
recirculation can cause thrombus formation. Alternatively, high-speed rotation of the impellor 
generates areas of higher shear rate which increases chances of hemolysis and may cause platelet 
activation. In order to mitigate this risk, the impellor blades have been optimized to minimize these 




Figure 7- The three durable left ventricular assit device (LVAD) models encountered in this work. (Left) the 
2nd generation HeartMate II axial flow LVAD with mechanical bearing, (middle)the third generation 
HeartWare HVAD centrifugal flow LVAD with a hydrodynamic thrust bearing, and (Right) third generation 
HeartMate 3 centrifugal flow LVAD which is fully magnetically levitated.  
1.5.2 Categorizing LVAD Candidates 
LVADs are intended for patients with dilated NYHA Class IV heart failure refractory to 
medical therapy, EF < 25%, PCWP > 20, SBP < 80, Cardiac Index < 2 L/min/m2 and VO2max < 
14 mg/kg/min. Contraindications include (but are not limited to) hypertrophic cardiomyopathy, 
severe lung disease, uncorrectable aortic insufficiency, severe independent right heart failure, PVR 
> 6 WU or transpulmonary gradient (TPG) >15, active bleeding, vascular disease, unresolved 
stroke, and intolerance to anticoagulation.  [23]   
INTERMACS has stratified NYHA Class IV further subcategories by clinical status. 
INTERMACS Class ranges from 1-7, where INTERMACS Class 1 constitutes patients are 
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experiencing critical cardiogenic shock, Class 2 are patients in progressive decline, Class 3 are 
stable but inotrope dependent, Class 4 have resting symptoms, Class 5 are exertion intolerant, 
Class 6 are exertion limited, and group 7 are advanced NYHA Class III. INTERMACS class 2 and 
3 are the highest percentage of patients implanted with LVADs.[23, 24]  
When selecting patients for LVAD, the course of therapy must also be determined.  These 
are defined in four categories at time of implant but may change later.  The first is Bridge to 
Transplant (BTT), which, as the name states, is the group of patients who require mechanical 
circulatory support while awaiting transplant.  The second category is Destination Therapy (DT) 
which is intended for patients who are not candidates for transplantation.  For some time, those 
were the only two categories however to more have been added. Bridge to Decision (BTD) patients 
are those whose categorization as BTT or DT is unknown, and must be re-evaluated after sustained 
MCS, and Bridge to Recovery patients are those who are likely to experience substantial 
myocardial recovery while on MCS and may have the LVAD removed without needing a 
transplant.[12, 23, 25-28]  
1.5.3 Surgical Implantation 
The surgical process for LVAD implantation involves first placing a patient under general 
anesthesia.  Radial arterial line is placed to monitor arterial pressure along with Swann-Ganz 
catheter placed via jugular vein to monitor PA pressures throughout the procedure.  The 
anesthesiologist  places a TEE probe into the esophagus to assess the heart prior to surgery.  This 
evaluation includes looking for intracardiac shunts, cardiac thrombus, aortic insufficiency, and 
right ventricular failure.[29]    
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The surgeon then opens the chest via full sternotomy, followed by tunneling the 
percutaneous lead. The patient is then placed on cardiopulmonary bypass using arterial and venous 
cannulation. The apex of the LV is found and cored by the surgeon, who also inspects for any 
possible thrombus or anatomic obstructions. The LVAD inflow cannula is placed in the apical core 
with the inlet directed towards the mitral valve.  The LVAD is sutured to an apical cuff to secure 
it in place. The outflow graft is anastomosed to the ascending aorta as it is being de-aired and is 
then clamped. The heart and pump are then also de-aired.  The LVAD is turned on and brought to 
a low-speed setting until de-airing has been completed. CPB is slowly weaned as pump speed is 
increased until full LVAD support is reached. The anesthesiologist then evaluates the heart again, 
looking for air, obstruction, cannula malposition, aortic insufficiency, and RV dysfunction.[29] 
Speed settings are based on the TEE, arterial pressure, CVP, and PA pressure signals.  Finally, the 
TEE probe is removed, the chest is closed, and the patient is taken to the ICU and  [30-32] 
 
1.5.4 LVAD Physiology 
Modern durable LVADs generate continuous flow. During normal operation they provide 
total- or near-total support of the LV; almost no blood is ejected across the aortic valve, meaning 
the LV is completely unloaded (Figure 8). Some LVADs are designed to have periodic speed 
changes to help prevent thrombus formation near the aortic valve and pump.  In addition to speed 
modulation, there remains some native LV function, and thus there may be some fluctuation in 
flow albeit extremely dampened.[21, 33]. 
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Figure 8- Normal direction of blood flow in setting of left ventricular assist device at full support, and the 
resultant unloading of the LV. LVAD = left ventricular assist device. 
The amount of flow generated by the continuous flow LVAD is not only a function of 
speed, but also a function of preload and afterload.  This relationship of speed, pressure difference 
across the valve and resulting flow is illustrated by an “H-Q” curve resembling the diagram shown 
in Figure 9. The “Q” stands for flow, and the “H” stands for pressure head, or rather the difference 
between afterload minus preload (ΔP ) across the LVAD.  For instance, if a patient is hypertensive, 
or dehydrated,  afterload increases, or preload decreases, respectively.  This will increase ΔP that 
the pump must face and result in reduced flow.  The opposite also holds true: if, for instance, a 
patient is volume overloaded,  preload increases, ΔP decreases, and resulting flow increases. 
Different pump designs have different sensitivities to preload and afterload.  The steepness of the 
curves, and the changes due to pump speed act as a fingerprint for the device.  
The objective of determining the proper pump setting is to balance the desired pump output 
while not overdriving the pump, creating suction[34, 35] , and/or overloading the RV, which does 
not have mechanical support and may have previously unknown dysfunction.  If suction occurs, 
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or RV failure occurs, the LVAD output will drop, the LV will not remain unloaded, and the patient 
may once again begin to experience heart failure symptoms.    
 
Figure 9- Example of how an “H-Q Curve” may look like for a specific continuous flow LVAD. A change in 
speed or in pressure may increase of decrease the resulting pump flow. Depending on the pump design, the 
curves may be steeper of flatter base on sensitivity to afterload. ΔP = Pressure drop across the pump (the 
difference of afterload minus preload), L/min = liters/ min. 
1.5.5 Right Ventricular Failure post-LVAD Implantation 
RV failure post-LVAD implant has been a complication faced by patients since first-
generation LVADs have been in use [36]. To date, there remains a great need to improve the ability 
to predict and monitor RV dysfunction as well as gauge response to treatment to improve overall 
outcomes with LVAD support.  
Kormos et al previously reported that the one-year survival of patients who have received 
a HeartMate II LVAD as bridge to transplant with early RVF is nearly 20% less than that of 
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patients with the same device who do not have RVF [37]. Results vary for incidences of RVF post-
LVAD in the literature, mainly due to differences in its definition, however it has been reported to 
range from 9% to 40% as summarized by Patlolla et al. [38] However, it is known RVF results in 
a decrease in survival to transplant or continued support, and an increase in hospital stay. In the 
most severe RVF cases, MCS for the RV is needed.  Short-term RV MCS is available; however, 
no durable RVAD currently exists.[39] 
RV Failure can occur either early (acute) or late after implant (chronic). Much work has 
been done to study the former, including novel indices, risk scores and decision support systems; 
studies of chronic RV failure are less common.[37, 40-50]  Even when RV function is normal prior 
to LVAD implantation, surgical events and the altered physiology of mechanical support may 
result in RVF. The sudden increase in output from an LVAD and resulting demand placed on the 
right heart can bring about signs of RV failure that go unnoticed when venous return was minimal 
prior to implant. RV dysfunction due to LVAD implantation can also occur due to septal shift 
caused by unloading of the LV (see Figure 10), resulting in increased RV compliance, and 
decreased RV contractility.[36]  Additionally, in some patients, elevated pulmonary vascular 
resistance (PVR) may persist, even after the pulmonary capillary wedge pressure has decreased 
due to unloading by the LVAD [51].  
RV function is difficult to assess, due in part to its complex crescent-shaped geometry and 
its interactions with the left ventricle and septum. Comprehensive assessment of RV function, 
afterload, and coupling are necessary for characterization of the pulmonary circuit. This requires 
both imaging and invasive hemodynamic assessment.[52]  
Conventional transthoracic echocardiography (TTE) and transesophageal 
echocardiography (TEE) are common techniques use to assess RV function, and right heart 
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catheterization is performed to assess pressures and cardiac output. What has yet to be done is the 
full investigation of the RV afterload in the frequency domain, using pulmonary vascular 
impedance, to determine if there is a difference between patients who experience RV failure 
(RVF). 
Using only the standard of care procedures described in the previous sections, it is the 
intention of this study to develop a method of analyzing PVZ for LVAD recipients during the pre- 
and perioperative phase of LVAD implantation. The goal is to determine if there are differences 
in PVZ between patients who suffer from chronic RV Failure post implant and those who do not.  




Figure 10- Direction of blood flow in setting of RV Failure post-LVAD implant.  Altered geometry of RV and 
LV due to overload of the RV and unloading of LV can cause septal shift, resulting in RV dysfunction. 
Thickness of white arrows arrows are proprtional to flow. RV = right ventricle; LVAD = left ventricular assist 
device. 
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2.0 Hemodynamic Assessment of Pre- and Perioperative Afterload as an indicator of 
Chronic RV Failure post-LVAD Implant   
As stated in Chapter 1, PVZ is the most effective way to describe the entire RV afterload. 
It also has not been used in the clinical setting due to technical, logistical, and financial challenges. 
This study sought to determine whether there was a difference in the RV afterload of LVAD 
patients who experience RV failure post implant. We attempted to do so using standard of care 
hemodynamic studies via right heart catheterization to evaluate afterload in the time domain, and 
then combined the waveforms with pulsed-wave doppler velocities obtained via TTE and TEE to 
generate a composite PVZ to characterize the oscillatory and steady components of RV afterload 
in the frequency domain. We did so at multiple timepoints leading up to and during LVAD 
implantations to evaluate afterload at different hemodynamic states that are known to occur. The 
following chapter discusses these studies in detail. 
2.1 Ethical Considerations 
Prior to LVAD evaluation and implant, patients who are LVAD candidates consent to 
allow data acquired during standard of care to be used for research purposes. Because the data we 
obtained were already being obtained during standard of care echoes and RHCs, the need for 
further consent was waived. Confirmation from the University of Pittsburgh Institutional Review 
Board was received before proceeding with the study. 
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2.2 Data Acquisition and Timeline 
Starting in 2016, pulmonary arterial pressure (PAP) waveforms and/or PA Pulsed Wave 
Doppler (PW Doppler, or just Doppler) velocity (and ultimately flow (PAQ)) waveforms were 
captured during standard of care procedures performed during the pre-, peri-, and acute post-
operative timepoints of patients who received durable LVAD support. The data were used to 
calculate hemodynamic measures of RV afterload in both the time and frequency domains.  Each 
timepoint corresponds to a known change in state of the patient which may affect afterload, and 
thus provide further insight into potential for RV failure.  
As illustrated in Figure 11, both pressure and flow data were acquired at three separate 
time points (T) for this study: Data from T(1) was retrospectively obtained from hemodynamic 
and echocardiographic studies performed separately while subjects were evaluated for possible 
durable LVAD support. Data from T(2) and T(3) were both acquired prospectively in the operating 
room with patients anesthetized; either pre-sternotomy or with chest open, off-bypass and on full 
LVAD support, respectively. Pressure-only data were acquired for an additional two time points: 
T(4) immediately following chest closure in the OR, and T(5) within 4-24 hours of chest closure 
with patient in the intensive care unit (ICU). No PW Doppler velocities were obtained at T(4) and 
T(5) because it is standard practice to remove the TEE probe prior to chest closure and transport 




Figure 11- Study Timeline describing how data were obtained, location, status, level of LVAD support, and 
data sources available at each timepoint.  The red arrow indicates progression of time, and the blue arrow 
indicates timepoint at which LVAD support has started (T(3)).  
 
This study included patients who were over the age of 18 and evaluated for durable LVAD 
as bridge to transplant (BTT) or destination therapy (DT). Patients with prior LVAD (device 
replacement), temporary RVAD support or ECMO support prior to surgery were excluded from 
this study. Patients were censored from the study if, before POD 365 sans RVF, death or cardiac 
transplant occurred. RV failure was determined by chart review of ICD 10 codes and expert 
adjudication of patient records using INTERMACs definitions at the time.[53]  
Screen captures of pre-operative pressure waveforms acquired in the catheterization lab via 
Phillips system (Philips North America Corporation, Andover, MA, USA) were saved as JPEG or 
Bitmap images. Pressure waveforms recorded in the OR were captured and sent to a standard 
printer by a GE Datex Ohmeda Anesthesia system (GE Healthcare, USA). In the ICU, pressure 
waveforms were also printed by standard printer from the nurse’s station.  Paper printouts were 
then re-scanned by a standard office copier/scanner as PDFs at a resolution of 600DPI and later 
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converted to JPEG images. TTE and TEE images of both PA PW Doppler velocities and 
parasternal short axis views of the base of the heart were downloaded as JPEG images from 
electronic health records. 
Signals were re-digitized using previously published custom-written MATLAB software 
(MathWorks, Natick Mass, USA). [54] Briefly, images were calibrated using a known scale and 
waypoints were then added to the waveforms at minima, maxima, inflexion points, and regions of 
changing slope. The waypoints were then used to fit a piecewise spline curve, that would then be 
resampled at 1kHz.  The re-digitized signals could then be exported for further analysis. Figure 12 
shows examples of traced screen captures of Doppler echo and right heart catheter signals obtained 
during surgery. 







Figure 12- Examples of traced signals that were obtained during the perioperative period. (Top Left) 
Parasternal short axis view taken at base of the heart during a transesophageal echo, and measurement of 
pulmonary artery diameter. (Top Right) Tracing of Pulsed-wave Doppler signal and ECG signal obtained 
during transesophageal echo. (Bottom) Tracing of pulmonary arterial pressure signal obtained from Swann-
Ganz catheter in operating room, and ECG signal. 
 
As shown in Table 1, a total of 51 LVAD recipients were included in this cohort (8 female; 
27 ischemic) age 57±12 yrs. Within 365 post-op days (POD), 9 subjects experienced RVF with a 
mean time to diagnosis of 176±111 days, two of whom also required greater than 14days of post-
operative inotropic support. Ultimately, 11 subjects were censored amongst all 51 subjects (6 
deceased, 5 Transplant) prior to the 1-year endpoint or experiencing RVF. Figure 13 shows 
quarterly count of studies attended during the data collection phase of this work and is color coded 
based on the device implanted.  Early in the study, implants where data were acquired were 
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comprised mainly of HeartWare and HeartMate II devices.  However, towards the second half of 
the study, Heartmate 3’s were encountered more frequently. 
 
Table 1- Patient Cohort 
  Total No RVF Chronic RVF 
N (n female) 51 (8) 42 (5) 9(3) 
Age mean±SD 56±12 56±12 59± 15 
Non-ischemic 24 19 5 
INTERMACS Class 1 11 9 2 
INTERMACS Class 2 12 10 2 
INTERMACS Class 3 21 18 3 
INTERMACS Class 4 7 5 2 
HeartMate II 8 8 0 
HeartMate 3 13 12 1 
HeartWare HVAD 30 22 8 
Post-op Inotropes > 14 days 7 5 2 
Time to chronic RVF (days) - - 176±111 




Figure 13-Quarterly count of studies where data were acquired, color coded by device. Early in the study, 
implants where data were acquired were comprised mainly of HeartWare and HeartMate II devices.  However, 
towards the second half of the study, Heartmate 3’s were encountered more frequently. Qtr = quarter 
 31 
2.3 Assessment of RV Afterload in the Time Domain 
2.3.1 Description 
The initial assessment of patient data involved commonly measured and reported 
hemodynamic parameters found in the time domain.  Therefore, in addition to the waveforms that 
were redigitized, discrete mean values, on each sheet or in each report, such as central venous 
pressure, mean aortic pressure, etc. were included in this portion of the study. PCWP was recorded 
only for T(1), as that was the only timepoint where it was available.  
2.3.2 Methods 
Redigitized PAP waveforms were imported into custom MATLAB software that allowed 
selection of multiple, nonsequential beats.  An attempt was made to select at least three beats, but 
fewer were selected if necessary.  From the multiple beat selections, an average representative beat 
(ARB) was calculated at each available timepoint for each subject.  
Using the ARBs, the mean, systolic, and diastolic pressures were recorded; heart rate was 
calculated as the inverse of the cycle period, PA pulse pressure was calculated as the difference 
between PA systolic and PA diastolic pressures.  CVP and RAP were used interchangeably, as 
was PA diastolic pressure and PCWP.  This allowed for an estimation of pulmonary arterial 
pulsatility index (PAPi), calculated as PA pulse pressure divided by RA pressure, which has been 
frequently used when studying RVF in the acute and short-term.[55] The ratio of CVP/PCWP, as 
reported, was also estimated. [39, 56, 57] 
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2.3.3 Statistical Methods 
Comparisons between values for subjects with RVF and without RVF at each time point 
for each parameter were conducted using a Kruskal Wallis H-test. Rate of change for individual 
parameters between timepoints was also attempted at T(2) to T(3). Finally, a mixed effects mixed 
effects model was attempted for the rate of change for mPAP and PAPi, as these were determined 
to be the most likely to have a difference between groups when tested with a pilot set of the data 
during initial consultation with a biostatistician, and PAPi has shown significance in subjects who 
experience RVF acute post-op.   
2.3.4 Results 
At least one screen capture of PAP waveforms was obtained for each of the 51 subjects. 39 
subjects had recordings at all timepoints. Reasons for 12 subjects missing at least one data point 
include no pre-op RHC recorded at the institution, catheter malfunction, incorrect positioning, 
poor signal quality, or early removal prior to 24 hours post chest closure. The composition of the 
dataset is illustrated in Figure 14, which shows number of captures and outcome for each subject. 
An example of the of the ARBs and hemodynamic values are shown in Figure 15.  (Note that 
although only 51 subjects were included in the cohort, 52 studies were observed.  At the request 
of the surgeon, this subject was excluded from the study as it was determined that patient required 
simultaneous pulsatile Bi-VAD support immediately prior to surgery). 
Figure 16 shows median and 95% confidence plotted for each hemodynamic parameter, 
grouped by subjects with RVF and for subjects without RVF at each time point.  Minimal 
separation was found between median values and a wide range for most confidence intervals can 
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be seen. Differences between standard hemodynamics in the time domain (mPAP, PAPsys, 
PAPdia, Pulse Pressure, CVP (or RAP)) as well as PAPI were not significant at any T between 




Figure 14-(Top) Visual representation of presure data acquired per patient by stage. (Bottom) pressure data 
acquired per patient by outcome. Abbreviations: (-)RVF = no RV failure, (+)RVF = RV Failure, TX = 
transplant before one year, DEC = deceased before one year, EXC = excluded from study per surgeon request. 
Although only 51 subjects were included in the cohort, 52 studies were observed.  At the request of the surgeon 









Figure 15- (Left) Average representative beats (ARBs) for each timepoint.  (Right) Parameters derived by from 
each ARB at each timepoint.  (Bottom) Conditions for each timepoint. (Abbreviations: PA= Pulmonary Artery, 
PAP = PA pressure (mmHg), s = systolic, d = diastolic, m = mean, HR= heart rate (beats/min), MAP = Mean 
Aortic Pressure (systemic, mmHg), RAP = right atrial presure (mmHg), CVP= central venous pressure 




Figure 16- Pressure-derived parameters in the time domain versus timepoint (T) for subjects with RVF (Red) 
and without RVF (Blue). Vertical line at T(3) indicates timepoint of LVAD implant. (Abbreviations: RVF = 
right ventricular failure; PA= Pulmonary Artery, PAP = PA pressure (mmHg), sys = systolic, dia = diastolic, 
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m = mean, MAP = Mean Aortic Pressure (systemic, mmHg), RAP = right atrial presure (mmHg), CVP= central 
venous pressure (mmHg), PCWP = pulmonary capillary wedge pressure (mmHg), PAPi = PA pulsatility index.   
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2.4 Assessment of RV Afterload in the Frequency Domain using Pulmonary Vascular 
Impedance 
2.4.1 Description 
Pulsed-wave Doppler velocity signals were recorded when possible to calculate PVZ in the 
frequency domain. Because standard surgical protocol includes the removal of a TEE probe before 
chest closure, Doppler velocities were recorded for T(1), T(2), and T(3) only, and therefore only a 
subset of the data was used for calculation of PVZ. Using this smaller group of patients, afterload 
in the frequency domain was calculated to determine if there was a difference in PVZ between 
subjects with chronic RVF and those with no RVF. 
2.4.2 Methods 
Single beats were selected for both PAQ and Harmonics (z) of waves were calculated by 
Fast Fourier Transform (FFT) within MATLAB (MathWorks, Natick, MA, USA). PVZ(z) was 
calculated as FFT(P(t))/FFT(Q(t)). Total pulmonary resistance Z(0); characteristic impedance Zc, 
mean of PVZ(2-4); and vascular stiffness (Z1+Z2) were compared at T(1,2,3) between +/-RVF 
groups. 
2.4.3 Statistical Methods 
Comparisons at each individual time point for each Z0, Zc, and Z1+Z2, were conducted 
using a Kruskal Wallis H-test. Rate of change for individual parameters between timepoints was 
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also attempted between timepoints T(2) and T(3).  Results were deemed significant at p< 0.05. In 
the case of the study in the frequency domain, a mixed effects mixed effects model could not be 
attempted due to the lack of sufficient numbers in each group.   
2.4.4 Results 
Composition of the Doppler dataset is shown in Figure 17.  PVZ was able to be calculated 
for at least one time point for 43 of 51 subjects, including 7 with RVF. Retrospective PVZs could 
be constructed for n=  38 (6 with RVF).  The number of prospective PVZs for T(2) and T(3) were 
lower (17 ( 5 with RVF) and 18 (5 with RVF), respectively) due to no Doppler or pressure signals 
taken, technically difficult echo studies, difficult catheter placement, or malfunctioning catheter. 
On the other hand, there was a far larger window of time in which retrospective pressure and 
Doppler could be obtained. An example of a subject with all 3 PVZ spectra calculated is shown in 
Figure 18.  
Median time between PAQ and PAP at T1 was 2.7 days (range .02-60) and time to implant 
from last procedure was 3 days (range 1-37); median time between captures was .034 minutes 
(range .05-65) for T2 and T3.  Figure 19 shows the difference in heartrates for each subjects’ PAP 
and PAQ data at all timepoints. There was generally good agreement in HR between PAP and 
PAQ acquisitions. The largest difference was found in T1, likely due to wider range of time 
between data captures. The most extreme difference between heartrates occurred for one subject 
in T(2), due to arrhythmia.   
Figure 21 shows the mean and 95% confidence interval for all spectra for each group at 
each timepoint and parameter. General trends of decreasing Z0 and ZC, can be seen with all 
subjects combined, as one might expected due to optimization of patient hemodynamics 
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immediately prior to implant, followed by unloading due to the actual LVAD. However, it is also 
apparent that there is much overlap between outcome groups and large confidence intervals. A 
significant difference could only be found at T(1) for Z(1)+Z(2) with the full set of subjects. Data 
were then limited to captures that had a time difference of less than 96 hrs (see Figure 20), both 
between captures and from latest capture to surgery. The difference between groups was no longer 
significant when a time limit was imposed.  
 
Figure 17- Count of PA Doppler signals by stage and by outcome.  These waveforms, compined with pressure 
waveforms from previous section were used to calculat PVZ. Abbreviations: (-)RVF = no RV failure, (+)RVF 
= RV Failure, TX = transplant before one year, DEC = deceased before one year, EXC = excluded from study 
per surgeon request. Although only 51 subjects were included in the cohort, 52 studies were observed.  At the 




Figure 18- Components used for calculation of pulmonary vascular impedance (PVZ) and the resulting spectra 
from a single subject at all three timepoints. (Top left) Average representative beats for pressure. (Bottom left) 
Average representative beats for pulsed-wave Doppler velocity. (Top right) Modulus of the impedance 
spectrum. (Bottom right) Phase difference at each harmonic. Abbreviations: mmHg = millimeters of mercury, 





Figure 19- Heart rate comparisons for PVZ at all 3 timepoints. One subject at T(2) had an arrhythmia which 
caused the largest individual difference in heart rate. As a group, T(1) had the heart rate differences, likely due 






Figure 20-Shortest time to surgery for T(1) vs time between procedures (echocardiography and right heart 
catheterization for T(1)).  Large periods of time may have elapsed between subjects’ echo and right heart 
catheterization, or between last study and implant.  Comparison of PVZ by 1-year outcome was later limited 
to a maximum of 96 hours bewteencaptures , and 96 hours between last capture and surgery in order to 
decrease likelihood of error. PVZ = pulmonary vascular impedance, RHC = right heart catheterization. 
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Figure 21- PVZ  spectra and calculated parameter results for subjects with and without RVF (red, and blue, 
respectively). Dotted line indicates timepoint of device implant. A significant difference could only be found at 
T(1) for PVS  when using the full set of subjects. However, once data were limited to captures that had a time 
difference of less than 96 hrs (see Figure 20), both between captures and from latest capture to surgery, the 
data were no longer significant.Abbreviations: RVF = right ventricular failure. PVZ(z)  = pulmonary 
vascular impedance versus harmonic (z), ZS = stiffness, ZC = characteristic impedance, Z0 = total pulmonary 
resistance (steady component), CI = confidence interval.   
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2.5 Discussion 
Total afterload faced by the RV was successfully calculated via composite PVZ using only 
asynchronous standard of care pulsed-wave Doppler velocity and PA pressure. The waveforms 
were re-digitized and decomposed in the frequency domain via FFT, with PVZ calculated as 
PVZ(z)= P(z)/(Q(z). The shape of the impedance spectra resembles that which are generated via 
simultaneous recording of pressure and flow.  It is difficult to determine accuracy of the PVZ 
values because simultaneous acquisition has not yet been performed in LVAD subjects.  Also, 
since single beats were selected for PVZ (due to limitations with code), the results were more 
susceptible to high-frequency noise. If PCWP were known for all timepoints and subtracted from 
mean PA pressure, Z0 values would be lower because they would reflect PVR as opposed to TPR.  
The resulting PVZ spectra were grouped by RVF outcome out to one year. When grouped by RVF 
outcome out to one year, no difference in PVZ was found.  
Limitations in this study include small sample sizes, especially when calculating 
parameters in the frequency domain resulted in limited statistical testing. Time between captures 
in T(1) is likely a significant source of error. This is because pulmonary vascular impedance 
requires the assumption that the pulmonary vasculature is a linear time-invariant system. Many 
changes in hemodynamic state can change over several days, while short periods of time in 
between pressure and Doppler captures like those taken within the same timepoint in the OR are 
negligible.  Also, if a change did occur due to speed change of the pump or medication dosage 
change during implant, a new capture would be recorded after steady-state was reached. This could 
not be done for retrospective captures.   
While this work proved feasibility of PVZ assessment and provided pilot data, it would 
benefit from a structured prospective protocol with defined time limits for captures and a larger 
 46 
sample size. If this study were replicated in a larger cohort of patients, and the findings were 
confirmed, it would mean that future studies should focus on other components of the RV and 
pulmonary circulation at large, specifically function and coupling. 
With that said, it should be noted that after completion of this work, the definitions for RV 
failure have changed.  Kormos et al recently re-defined RV failure in order to facilitate more 
standardized clinical research involving mechanical circulatory support, including giving long-
term RVF its own designation.[58] Any re-analysis of this data or proposal of a larger study will 
need to use the new definitions moving forward. 
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3.0 Facilitation of Rapid Assessment of Pulmonary Vascular Impedance in the Clinical 
Setting 
3.1 Description 
Overload of the right ventricle (RV) frequently leads to heart failure and death. Therefore, 
characterizing the full afterload encountered by the RV is critical. The pulmonary vascular 
impedance (PVZ) spectrum, graphed in the frequency domain, is the only way to fully characterize 
the combined steady and pulsatile afterload faced by the right ventricle (RV).[59, 60] Analysis of 
PVZ to characterize the ventricular afterload has been performed for many decades in the research 
setting.[11, 59, 61-66] Unfortunately, current technical and cost limitations allow only the steady 
component (pulmonary vascular resistance (PVR) or total pulmonary resistance (TPR)) to be 
reported clinically.  
In Chapter 2.0 screen captures of pressure and Doppler velocity signals were redigitized 
by meticulously adding waypoints to an entire capture. Only then could the data be exported to a 
separate program for analysis, and another for compiling and reporting. So, while the earlier work 
has successfully shown that PVZ can be calculated using standard of care data, it was neither rapid 
nor intuitive. Both qualities are necessary for PVZ to become commonplace in the clinic and in 
clinical research. The solution is to create a graphical, stand-alone program that uses clinically 
available asynchronous pressure and Doppler velocity captures to calculate, display, and compile 
the PVZ spectra and its resulting parameters for clinicians and researchers. 
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3.2 Methods 
MATLAB-based software, called CompositePVZ©, was designed to analyze a patient’s 
afterload and its changes during a study. This required 3 items: 1) A parasternal short axis screen 
capture at the base of the heart from TTE or TEE for measuring diameter, (alternatively a known 
diameter value previously measured can be used as a substitute), 2) screen capture of PA pulsed-
wave Doppler velocity signal in the proximal PA from either TTE or TEE with ECG signal and 3) 
PA pressure signal with ECG signal obtained during standard right-heart catheterization. All of 
these can be obtained from standard RHC and Echo reports found in electronic health records 
(EHR).  
Each capture imported into the software is then be calibrated using scales commonly found 
on images. The diameter is measured (see   
Figure 22), and CSA is calculated by multiplying the diameter squared by pi/4.  
Redigitization of the pressure waveforms is performed by selecting a region that contains multiple 
beats from the signal of interest.  Once selected an automated border detection routine implements 
a time-frequency analysis function, called “tfridge” [67], within MATLAB that detects the signal, 
and traces it. The routine then overlays the signal on top of the image for inspection. The same 
task is then performed over the region containing the ECG signal in the same screen capture. Once 
completed for pressure, the process is repeated for pulsed-wave Doppler velocity and its ECG 
signal. Due to the low signal to noise ratio encountered with Doppler, manual editing of the traced 
Doppler signal may be performed by the user. An example of the traced signals for pressure and 
velocity is shown in Figure 23. 
Following re-digitization, the function resamples the waveforms at 1000 Hz. The product 
of V(t) and CSA is calculated to obtain flow (Q(t)). Mild noise reduction is performed via a 
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Savitzky-Golay filtering.[68]  Individual beats separated by R-R interval via the ECG signal are 
selected to generate individual beats for both P(t) and Q(t). The R-waves of the QRS signal are 
detected using a Pan Tompkins- based routine that was obtained as open-source code from 
MATLAB Central file exchange (See  
Figure 24). [69, 70] The individual beats are stacked on one another and are either selected 
or de-selected in order to generate an ARB.  
The ARBs are then decomposed into harmonics (z) via FFT, describing P(z) and Q(z) in 
the frequency domain. Modulus, calculated as the ratio of P(z) to Q(z) are plotted versus harmonics 
z(n) along with the phase difference between the two signals (see   
Figure 25).  Z(0) is the mean value of the signal, z(1) is equal to the fundamental frequency 
(reported in Hz as the inverse of heart rate), and higher harmonics z(2) through z(N) which are 
multiples of z(1). N is the maximum frequency from which PVZ can be determined by the fidelity 






Figure 22- Parasternal short axis view of the heart using 2-dimensionsionall ultrasound.  Two measurements 
are made: The measurement on the left is for calibration purposes, and the measurement on the right is 





Figure 23- (Top) Automated border detection of pulmonary arterial pulsed-wave Doppler velocity with 
electrocardiogram. Interference in the signal overlay can be observed at the end of the ECG signal. (Bottom) 
automated border detection from pulmonary arterial pressure waveform obtained via fluid-filled Swann Ganz 











Figure 25- (Left) selection of individual beats for generation of average representative beats (middle). The 
average representative beats decomposed into wavelets via Fast Fourier Transform to calculate Magnitude 





Figure 26 shows the resulting overlay of PVZ at two timepoints of a study involving the 
same subject under different conditions.  Additional parameters that are calculated include:Z0, Zc 
and stiffness (Z1+Z2), cardiac output, power, and location of the first minima.  The investigator 
can acquire multiple captures and choose which to include and exclude. The workflow is similar 
to cardiac output calculations in the catheterization lab. Parameters from selected spectra are then 
plotted and can be exported as a table for further analysis. A full display of the graphical user 
interface and all steps for analysis is featured in Appendix A, and a video of the software in use 
has been submitted along with this document (Video 1).  
Signal interference provided some difficulty with beat separation and analysis. Interference 
was most often observed when overlap of text and ECG occurred, obscuring an R-wave.  Other 
issues that were problematic included ECG noise or arrhythmia.  This occurred most frequently 
with pulsed-wave Doppler waveforms due to the layout of the image, the low signal to noise ratio, 
and the number of beats that were included in the image. An example of overlay interference can 
be seen towards the end of the Doppler ECG in Figure 23. Despite this, corrections to the image 
prior to importation, such as erasing text or tick marks in an image editing program, improved R-




Figure 26- (Top Left) Multiple impedance spectra can be calculated and overlayed from the same capture to 
show changes due to beat selection.  Addintionally, spectra can be calculated for multiple timepoints to observe 
changes during a protocol.  (Bottom Left) The end use has the ability to select which spectra to keep and whch 
to hide by checking the “Include” boxes for spectra of choice.  (Right) Time series for the resulting parameters 
from both time and frequecy domain are plotted for the selected spectra.  
 56 
3.4 Discussion 
A graphically driven analysis of PVZ, calculated from standard of care right heart 
catheterization and echocardiography is possible. A system such as this can enable clinicians to 
rapidly assess the afterload faced by a patient’s RV. However, due to the asynchronous manner in 
which the data is obtained, care should be taken to minimize time between TTE or TEE and right 
heart catheterization and to ensure that heart rates and rhythms are similar to avoid error.  If these 
limitations can be avoided, multiple clinical applications exist, including drug studies, exercise 
studies, and evaluations of surgical interventions that alter afterload. 
Future versions of the software will include ways to manually edit overlay interference 
within the program, such as blocking out regions where text or tick marks which may cause the 
tracing to deviate from the actual signal.   Selection of filtering technique and filter strength will 
also need to be made adjustable.  One final feature is a standardized report generator to go along 




4.0 Conclusions and Future Directions 
LVAD recipients who suffer from RVF post implant experience decreases in survival to 
transplant or continued support and increases in hospital stay.  While many investigators have 
studied RVF in the acute and short-term, few have studied potential causes for chronic RVF.  The 
work contained herein attempted to characterize the total afterload faced by the RV using PVZ 
calculated from standard of care procedures. Specifically, pulsed-wave Doppler velocity and PA 
pressure waveforms obtained pre- and perioperatively were recorded at timepoints of known 
hemodynamic change during implant. The waveforms were re-digitized and decomposed in the 
frequency domain via FFT, with PVZ calculated as PVZ(z)= P(z)/(Q(z). The resulting PVZ spectra 
were grouped by RVF outcome out to one year. No difference was found between groups. 
Finding no difference in pre- and perioperative PVZ in LVAD patients with RVF does not 
mean that this dissertation was unsuccessful.  Rather, it gives future direction for investigators.  
RV function, afterload, and coupling are all important facets of pulmonary circulation.  If this 
study were replicated in a larger cohort of patients, and the findings were confirmed, it would mean 
that future studies should focus on coupling and function.  Such studies would require the use of 
more advanced imaging techniques and measurement of pressure-volume loops, both require 
scarce resources and further justification for use. 
In the past, calculation of PVZ would fall into the same category requiring high-fidelity 
micromanometry acquired simultaneous to echo.  However, in addition to possibly ruling out 
perioperative afterload as a cause for chronic RVF, this work has shown that PVZ can be calculated 
in a manner that requires only data that already exists from standard of care echo and RHC. In the 
initial study, the re-digitization and calculation of PVZ with this data was labor intensive and 
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required several tools to complete the analysis.  However, after learning from this initial technique, 
a new system was developed that can complete the same analysis using the same EHR but in a 
single graphically driven software package that resembles the workflow of RHC systems found in 
the clinical setting.  
The use of CompositePVZ© is not limited to the analysis of data from a single patient 
suffering from Class IV HFrEF who received an LVAD. It can also potentially assist in 
determining the efficacy of other treatments that are thought to affect the RV afterload. For 
instance, members of the lab in which this dissertation was completed have previously studied 
novel drug treatments for WHO functional class II and III patients suffering from PH-HFpEF. In 
one such  study PVZ was calculated in 14 subjects from a single center using simultaneously 
recorded pressure and Doppler velocity waveforms captured before and after inhalation of sodium 
nitrite. It was found that inhaled sodium nitrite decreased Zc in subjects and increased RV 
efficiency and work. [71]    While this was a subset of a single-center early Phase IIa safety and 
efficacy trial, the simplification of asynchronous acquisition (with limitations on time between 
pressure and echo) and the ability to process simple screen captures creates the possibility of using 
the CompositePVZ© software for core analyses in larger-scale, multicenter trials.[72] 
Further work, however, needs to be performed to determine the limitations of this system.  
The maximum period between echo and pressure captures needs to be determined. The maximum 
period may differ for use with individual clinical patients who are stable and resting, as opposed 
to studies where hemodynamic state changes occur rapidly, such as drug or exercise studies.  Also, 
the method of PA pressure measurement needs to be considered. The maximum frequency used in 
calculations of impedance at higher harmonics (i.e., Zc), will need to be standardized for fluid-
filled catheters.   Once the questions have been thoroughly examined, we may likely see PVZ used 
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more frequently in the clinical setting, specifically in catheterization labs that are part of centers 




Screen captures of full GUI layouts for all tabs in CompositePVZ© can be found in this 




Appendix Figure 1- Step 1: Input subject info and import parasternal short axis view at base of the heart (TTE 
or TEE).  The inamge is calibrated using the images calibration key (the dots on the sector).  Following 
calibration, the diametetr of the PA is measured at the insertion sites of the PA valve leaflets.  
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Appendix Figure 2- Step2: The screen capture of pressure with ECG is imported.  Values the image is calibrated 
by assigning values to the x-axis, y-axis, and origin.  The user drags a boxes around the region containing the 
pressure waveforms.  Automated border detecttion then traces and re-digitizes the selected signals. 
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Appendix Figure 3- Step3: The screen capture of PA pulsewave Doppler signal is imported. This can be 
captured either via TTE or TEE.  Values the image is calibrated by assigning values to the x-axis, y-axis, and 
origin.  The user drags a boxes around the region containing the doppler and ECG waveforms.  Automated 
border detecttion then traces and re-digitizes the selected signals. Due to low signal-to-noise ratio in Doppler 
signals, the user can make edits to remove any artifacts in Doppler tracing.  
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Appendix Figure 4- Step 4: individual beats are automatically identified using ECG signal to generate an R-R 
interval. If unsatisfactory, user can repeat steps 2 and/or 3 to improve signal fidelity.  
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Appendix Figure 5- Step 5: User selects pressure and velocity beats to form average representative beats in tie 
domain and perform FFT to calculate a PVZ spectra. The user has the option of recording notes.  Once satisfied 
with spectra, user saves it to PVZ History for comparison. 
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Appendix Figure 6- Step 6: The user selectes which PVZ spectra to compare graphically by checking or 
unchecking boxes in bottom left table.  Spectra that are selected remain visble, and paraters derived from 
spectra are plotted in series on the right.  All data (both selected and unselected) are exported in a .csv file once 
complete.  The spreadsheet indicates which spectra were selected and deselected.  
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